Banners
22 people are looking at this moment
Lagevrio (other name Movfor)
- Active Ingredient:
- In Stock: Only 19 packs left
- Diseases:
- Lagevrio (other name Movfor) other names:
Molnupiravir, an Oral Antiviral Treatment for COVID-19
-
Lagevrio (other name Movfor) 200mg
Package Per Pill Special Price 200 caps Free Express Delivery $5.49 $1466 -26% Only $1097 160 caps Free Express Delivery $5.60 $1173 -24% Only $896 120 caps Free Express Delivery $5.79 $880 -21% Only $695 80 caps Free Express Delivery $6.18 $587 -16% Only $494 40 caps Free Regular Delivery $7.33 Only $293
Product Description
Common use
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.
Dosage and direction
Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days.
Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.
Results
Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.
Conclusions
Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.
testimonials
Angle P “I have never been this happy with an online service in my life. The shipping is quick, and the service is easy to use.”